Published in Int Arch Allergy Immunol on December 20, 2014
Direct gene transfer into mouse muscle in vivo. Science (1990) 10.39
Heterologous protection against influenza by injection of DNA encoding a viral protein. Science (1993) 10.14
Genetic immunization is a simple method for eliciting an immune response. Nature (1992) 5.30
Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov (2006) 5.19
Assessing the efficacy of oral immunotherapy for the desensitisation of peanut allergy in children (STOP II): a phase 2 randomised controlled trial. Lancet (2014) 4.36
Clinical efficacy and immune regulation with peanut oral immunotherapy. J Allergy Clin Immunol (2009) 3.91
Oral gene delivery with chitosan--DNA nanoparticles generates immunologic protection in a murine model of peanut allergy. Nat Med (1999) 3.36
Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis. N Engl J Med (2006) 3.25
Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol (2001) 3.19
Effect of anti-IgE therapy in patients with peanut allergy. N Engl J Med (2003) 3.00
A randomized controlled study of peanut oral immunotherapy: clinical desensitization and modulation of the allergic response. J Allergy Clin Immunol (2011) 2.77
Mucosal delivery of therapeutic and prophylactic molecules using lactic acid bacteria. Nat Rev Microbiol (2008) 2.58
Food Allergy Herbal Formula-1 (FAHF-1) blocks peanut-induced anaphylaxis in a murine model. J Allergy Clin Immunol (2001) 2.51
Oral peanut immunotherapy in children with peanut anaphylaxis. J Allergy Clin Immunol (2010) 2.50
Treatment of anaphylactic sensitivity to peanuts by immunotherapy with injections of aqueous peanut extract. J Allergy Clin Immunol (1997) 2.35
Treatment of peanut allergy with rush immunotherapy. J Allergy Clin Immunol (1992) 2.29
Peanut allergy: emerging concepts and approaches for an apparent epidemic. J Allergy Clin Immunol (2007) 2.22
Prevalence of challenge-proven IgE-mediated food allergy using population-based sampling and predetermined challenge criteria in infants. J Allergy Clin Immunol (2011) 2.13
Safety of a peanut oral immunotherapy protocol in children with peanut allergy. J Allergy Clin Immunol (2009) 1.98
Sublingual immunotherapy for peanut allergy: clinical and immunologic evidence of desensitization. J Allergy Clin Immunol (2011) 1.93
The natural history of peanut allergy. J Allergy Clin Immunol (2001) 1.89
Successful oral tolerance induction in severe peanut allergy. Allergy (2009) 1.86
Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy (2004) 1.84
Allergy or tolerance in children sensitized to peanut: prevalence and differentiation using component-resolved diagnostics. J Allergy Clin Immunol (2010) 1.84
Efficacy and safety of high-dose peanut oral immunotherapy with factors predicting outcome. Clin Exp Allergy (2011) 1.81
The Chinese herbal medicine formula FAHF-2 completely blocks anaphylactic reactions in a murine model of peanut allergy. J Allergy Clin Immunol (2005) 1.77
Sublingual immunotherapy: World Allergy Organization position paper 2013 update. World Allergy Organ J (2014) 1.74
Sustained unresponsiveness to peanut in subjects who have completed peanut oral immunotherapy. J Allergy Clin Immunol (2013) 1.73
Peanut allergy. Lancet (2008) 1.72
Efficacy and mechanisms of action of traditional Chinese medicines for treating asthma and allergy. J Allergy Clin Immunol (2009) 1.71
Probiotics and prebiotic galacto-oligosaccharides in the prevention of allergic diseases: a randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol (2006) 1.66
State of the art on food allergen immunotherapy: oral, sublingual, and epicutaneous. J Allergy Clin Immunol (2014) 1.60
Peanut oral immunotherapy modifies IgE and IgG4 responses to major peanut allergens. J Allergy Clin Immunol (2012) 1.56
Allergen-specific oral immunotherapy for peanut allergy. Cochrane Database Syst Rev (2012) 1.51
The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy (2005) 1.51
Overall prevalence of self-reported food allergy in Canada. J Allergy Clin Immunol (2012) 1.49
Peanut oral immunotherapy results in increased antigen-induced regulatory T-cell function and hypomethylation of forkhead box protein 3 (FOXP3). J Allergy Clin Immunol (2014) 1.49
Oral immunotherapy for the treatment of peanut allergy: systematic review of six case series studies. Prim Care Respir J (2012) 1.48
Anaphylaxis: can we tell who is at risk of a fatal reaction? Curr Opin Allergy Clin Immunol (2004) 1.47
Identification and mutational analysis of the immunodominant IgE binding epitopes of the major peanut allergen Ara h 2. Arch Biochem Biophys (1997) 1.47
Molecular cloning and epitope analysis of the peanut allergen Ara h 3. J Clin Invest (1999) 1.47
Mapping and mutational analysis of the IgE-binding epitopes on Ara h 1, a legume vicilin protein and a major allergen in peanut hypersensitivity. Eur J Biochem (1997) 1.45
Food Allergy Herbal Formula-2 silences peanut-induced anaphylaxis for a prolonged posttreatment period via IFN-gamma-producing CD8+ T cells. J Allergy Clin Immunol (2009) 1.41
Peanut epitopes for IgE and IgG4 in peanut-sensitized children in relation to severity of peanut allergy. J Allergy Clin Immunol (2008) 1.39
Effects of intestinal microflora and the environment on the development of asthma and allergy. Springer Semin Immunopathol (2003) 1.35
Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis. J Allergy Clin Immunol (2002) 1.34
Safety, tolerability, and immunologic effects of a food allergy herbal formula in food allergic individuals: a randomized, double-blinded, placebo-controlled, dose escalation, phase 1 study. Ann Allergy Asthma Immunol (2010) 1.31
A phase II, randomized, double‑blind, parallel‑group, placebo‑controlled oral food challenge trial of Xolair (omalizumab) in peanut allergy. J Allergy Clin Immunol (2011) 1.30
Quantification of specific IgE to whole peanut extract and peanut components in prediction of peanut allergy. J Allergy Clin Immunol (2011) 1.29
Induction of tolerance after establishment of peanut allergy by the food allergy herbal formula-2 is associated with up-regulation of interferon-gamma. Clin Exp Allergy (2007) 1.27
Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol (2006) 1.26
Sublingual immunotherapy for peanut allergy: a randomized, double-blind, placebo-controlled multicenter trial. J Allergy Clin Immunol (2013) 1.24
The pharmacological basis of anti-IgE therapy. Nat Biotechnol (2000) 1.20
Effector activity of peanut allergens: a critical role for Ara h 2, Ara h 6, and their variants. Clin Exp Allergy (2009) 1.17
Epicutaneous immunotherapy results in rapid allergen uptake by dendritic cells through intact skin and downregulates the allergen-specific response in sensitized mice. J Immunol (2011) 1.17
Does skin prick test reactivity to purified allergens correlate with clinical severity of peanut allergy? Clin Exp Allergy (2007) 1.16
Persistent protective effect of heat-killed Escherichia coli producing "engineered," recombinant peanut proteins in a murine model of peanut allergy. J Allergy Clin Immunol (2003) 1.16
Ara h 1-reactive T cells in individuals with peanut allergy. J Allergy Clin Immunol (2011) 1.15
Heat-killed Listeria monocytogenes as an adjuvant converts established murine Th2-dominated immune responses into Th1-dominated responses. J Immunol (1998) 1.12
A pilot study of omalizumab to facilitate rapid oral desensitization in high-risk peanut-allergic patients. J Allergy Clin Immunol (2013) 1.11
Predictive value of skin prick tests using recombinant allergens for diagnosis of peanut allergy. J Allergy Clin Immunol (2006) 1.11
Probiotics in infancy induce protective immune profiles that are characteristic for chronic low-grade inflammation. Clin Exp Allergy (2008) 1.10
Mucosal co-application of lactic acid bacteria and allergen induces counter-regulatory immune responses in a murine model of birch pollen allergy. Vaccine (2003) 1.10
Allergenic characteristics of a modified peanut allergen. Mol Nutr Food Res (2005) 1.09
Clinical safety of Food Allergy Herbal Formula-2 (FAHF-2) and inhibitory effect on basophils from patients with food allergy: Extended phase I study. J Allergy Clin Immunol (2011) 1.08
Complementary and alternative medicine in pediatric allergic disorders. Curr Opin Allergy Clin Immunol (2009) 1.08
IgE cross-reactivity between the major peanut allergen Ara h 2 and the nonhomologous allergens Ara h 1 and Ara h 3. J Allergy Clin Immunol (2013) 1.07
Engineered recombinant peanut protein and heat-killed Listeria monocytogenes coadministration protects against peanut-induced anaphylaxis in a murine model. J Immunol (2003) 1.07
IgE to peanut allergen components: relation to peanut symptoms and pollen sensitization in 8-year-olds. Allergy (2010) 1.06
Sublingual versus oral immunotherapy for peanut-allergic children: a retrospective comparison. J Allergy Clin Immunol (2013) 1.06
Genetic modification removes an immunodominant allergen from soybean. Plant Physiol (2003) 1.04
Immunological mechanisms of sublingual allergen-specific immunotherapy. Allergy (2011) 1.04
Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma. Clin Exp Allergy (2008) 1.03
The effect of intravenous administration of a chimeric anti-IgE antibody on serum IgE levels in atopic subjects: efficacy, safety, and pharmacokinetics. J Clin Invest (1997) 1.03
Basophil histamine release decreases during omalizumab therapy in allergic asthmatics. Int Arch Allergy Immunol (2007) 1.03
RNA interference for wheat functional gene analysis. Transgenic Res (2007) 1.03
Omalizumab reverses the phenotypic and functional effects of IgE-enhanced Fc epsilonRI on human skin mast cells. J Immunol (2007) 1.02
Epicutaneous immunotherapy on intact skin using a new delivery system in a murine model of allergy. Clin Exp Allergy (2009) 1.01
Epicutaneous immunotherapy using a new epicutaneous delivery system in mice sensitized to peanuts. Int Arch Allergy Immunol (2010) 1.00
A bioinformatics approach to identify patients with symptomatic peanut allergy using peptide microarray immunoassay. J Allergy Clin Immunol (2012) 0.98
Ara h 2 peptides containing dominant CD4+ T-cell epitopes: candidates for a peanut allergy therapeutic. J Allergy Clin Immunol (2010) 0.98
In vivo and in vitro immunomodulation of Der p 1 allergen-specific response by Lactobacillus plantarum bacteria. Clin Exp Allergy (2007) 0.96
Multiple T cell epitope peptides suppress allergic responses in an egg allergy mouse model by the elicitation of forkhead box transcription factor 3- and transforming growth factor-beta-associated mechanisms. Clin Exp Allergy (2010) 0.96
Oral administration of IL-12 suppresses anaphylactic reactions in a murine model of peanut hypersensitivity. Clin Immunol (2001) 0.96
Grass pollen immunotherapy as an effective therapy for childhood seasonal allergic asthma. J Allergy Clin Immunol (2006) 0.96
Effectiveness and safety of orally administered immunotherapy for food allergies: a systematic review and meta-analysis. Br J Nutr (2013) 0.96
IL-21 induces inhibitor of differentiation 2 and leads to complete abrogation of anaphylaxis in mice. J Immunol (2007) 0.96
Omalizumab improves asthma-related quality of life in patients with severe allergic asthma. J Allergy Clin Immunol (2003) 0.95
Health-related quality of life of food allergic patients measured with generic and disease-specific questionnaires. Allergy (2010) 0.95
Engineering, characterization and in vitro efficacy of the major peanut allergens for use in immunotherapy. Int Arch Allergy Immunol (2001) 0.95
Increased peanut-specific IgA levels in saliva correlate with food challenge outcomes after peanut sublingual immunotherapy. J Allergy Clin Immunol (2012) 0.94
Soybean isoflavones regulate dendritic cell function and suppress allergic sensitization to peanut. J Allergy Clin Immunol (2011) 0.94
Oral immunotherapy with immunodominant T-cell epitope peptides alleviates allergic reactions in a Balb/c mouse model of egg allergy. Allergy (2011) 0.94
Effectiveness of subcutaneous immunotherapy for allergic rhinoconjunctivitis and asthma: a systematic review. Laryngoscope (2013) 0.92
Epicutaneous immunotherapy (EPIT) blocks the allergic esophago-gastro-enteropathy induced by sustained oral exposure to peanuts in sensitized mice. PLoS One (2012) 0.92
Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis. Ann Allergy Asthma Immunol (2003) 0.91
T cell epitope-based allergy vaccines. Curr Top Microbiol Immunol (2011) 0.91
Lactic acid bacteria as novel adjuvant systems for prevention and treatment of atopic diseases. Curr Opin Allergy Clin Immunol (2008) 0.91
A phase 1 study of heat/phenol-killed, E. coli-encapsulated, recombinant modified peanut proteins Ara h 1, Ara h 2, and Ara h 3 (EMP-123) for the treatment of peanut allergy. Allergy (2013) 0.90
Alleviating peanut allergy using genetic engineering: the silencing of the immunodominant allergen Ara h 2 leads to its significant reduction and a decrease in peanut allergenicity. Plant Biotechnol J (2007) 0.90
The Bet v 1 fold: an ancient, versatile scaffold for binding of large, hydrophobic ligands. BMC Evol Biol (2008) 2.15
Eosinophilic gastrointestinal disease suggestive of pathogenesis-related class 10 (PR-10) protein allergy resolved after immunotherapy. J Allergy Clin Immunol (2013) 2.06
Crystal structure of a hypoallergenic isoform of the major birch pollen allergen Bet v 1 and its likely biological function as a plant steroid carrier. J Mol Biol (2003) 1.99
Allergens are distributed into few protein families and possess a restricted number of biochemical functions. J Allergy Clin Immunol (2008) 1.77
Microarrayed allergen molecules: diagnostic gatekeepers for allergy treatment. FASEB J (2002) 1.66
Nomenclature and structural biology of allergens. J Allergy Clin Immunol (2006) 1.45
Novel allergens from ancient foods: Man e 5 from manioc (Manihot esculenta Crantz) cross reacts with Hev b 5 from latex. Mol Nutr Food Res (2013) 1.41
Apple allergy across Europe: how allergen sensitization profiles determine the clinical expression of allergies to plant foods. J Allergy Clin Immunol (2006) 1.30
Evolutionary biology of plant food allergens. J Allergy Clin Immunol (2007) 1.16
Evolutionary distance from human homologs reflects allergenicity of animal food proteins. J Allergy Clin Immunol (2007) 1.11
Mucosal co-application of lactic acid bacteria and allergen induces counter-regulatory immune responses in a murine model of birch pollen allergy. Vaccine (2003) 1.10
Plant-based heterologous expression of Mal d 2, a thaumatin-like protein and allergen of apple (Malus domestica), and its characterization as an antifungal protein. J Mol Biol (2003) 1.09
Pollen allergens are restricted to few protein families and show distinct patterns of species distribution. J Allergy Clin Immunol (2005) 1.09
IgE cross-reactivity between the major peanut allergen Ara h 2 and the nonhomologous allergens Ara h 1 and Ara h 3. J Allergy Clin Immunol (2013) 1.07
Crystal structure of the major celery allergen Api g 1: molecular analysis of cross-reactivity. J Mol Biol (2005) 1.06
Structural and immunologic characterization of Ara h 1, a major peanut allergen. J Biol Chem (2011) 1.03
Mutational analysis of amino acid positions crucial for IgE-binding epitopes of the major apple (Malus domestica) allergen, Mal d 1. Int Arch Allergy Immunol (2005) 1.02
Thaumatin-like proteins -- a new family of pollen and fruit allergens. Allergy (2004) 1.02
Naturally occurring hypoallergenic Bet v 1 isoforms fail to induce IgE responses in individuals with birch pollen allergy. J Allergy Clin Immunol (2007) 1.01
Structural relatedness of plant food allergens with specific reference to cross-reactive allergens: an in silico analysis. J Allergy Clin Immunol (2005) 0.97
Sequence variability of the pattern recognition receptor Mermaid mediates specificity of marine nematode symbioses. ISME J (2011) 0.94
Component-resolved diagnosis of kiwifruit allergy with purified natural and recombinant kiwifruit allergens. J Allergy Clin Immunol (2010) 0.91
Entamoeba histolytica: analysis of the trophozoite proteome by two-dimensional polyacrylamide gel electrophoresis. Exp Parasitol (2005) 0.91
Latex allergy within a cohort of not-at-risk subjects with respiratory symptoms: prevalence of latex sensitization and assessment of diagnostic tools. Int Arch Allergy Immunol (2007) 0.88
Inhibition of tumor cell growth by antibodies induced after vaccination with peptides derived from the extracellular domain of Her-2/neu. Int J Cancer (2003) 0.88
Differential T-cell responses and allergen uptake after exposure of dendritic cells to the birch pollen allergens Bet v 1.0101, Bet v 1.0401 and Bet v 1.1001. Immunobiology (2009) 0.87
Kiwifruit allergy across Europe: clinical manifestation and IgE recognition patterns to kiwifruit allergens. J Allergy Clin Immunol (2012) 0.86
Vaccination with a human high molecular weight melanoma-associated antigen mimotope induces a humoral response inhibiting melanoma cell growth in vitro. J Immunol (2005) 0.86
Cross-reactivity of peanut allergens. Curr Allergy Asthma Rep (2014) 0.86
Suppression of human melanoma tumor growth in SCID mice by a human high molecular weight-melanoma associated antigen (HMW-MAA) specific monoclonal antibody. Int J Cancer (2005) 0.85
Crystallization and preliminary structure determination of the plant food allergen Pru av 2. Acta Crystallogr Sect F Struct Biol Cryst Commun (2005) 0.85
Single-chain antibodies to the EWS NH(2) terminus structurally discriminate between intact and chimeric EWS in Ewing's sarcoma and interfere with the transcriptional activity of EWS in vivo. Cancer Res (2006) 0.84
Hevea brasiliensis latex allergens: current panel and clinical relevance. Int Arch Allergy Immunol (2005) 0.84
Specificity of mimotope-induced anti-high molecular weight-melanoma associated antigen (HMW-MAA) antibodies does not ensure biological activity. PLoS One (2011) 0.84
How accurate and safe is the diagnosis of hazelnut allergy by means of commercial skin prick test reagents? Int Arch Allergy Immunol (2003) 0.84
Component-resolved IgE profiles in Austrian patients with a convincing history of peanut allergy. Int Arch Allergy Immunol (2015) 0.83
Do lipids influence the allergic sensitization process? J Allergy Clin Immunol (2014) 0.83
Latex-allergic patients sensitized to the major allergen hevein and hevein-like domains of class I chitinases show no increased frequency of latex-associated plant food allergy. Mol Immunol (2010) 0.83
A novel concept for detoxification: complexation between aconitine and liquiritin in a Chinese herbal formula ('Sini Tang'). J Ethnopharmacol (2013) 0.83
Reduction of human melanoma tumor growth in severe combined immunodeficient mice by passive transfer of antibodies induced by a high molecular weight melanoma-associated antigen mimotope vaccine. Clin Cancer Res (2008) 0.82
Role of the polypeptide backbone and post-translational modifications in cross-reactivity of Art v 1, the major mugwort pollen allergen. Biol Chem (2009) 0.82
Effects of gastrointestinal digestion and heating on the allergenicity of the kiwi allergens Act d 1, actinidin, and Act d 2, a thaumatin-like protein. Mol Nutr Food Res (2008) 0.82
Delayed tumor onset and reduced tumor growth progression after immunization with a Her-2/neu multi-peptide vaccine and IL-12 in c-neu transgenic mice. Breast Cancer Res Treat (2007) 0.82
Specific IgE response to purified and recombinant allergens in latex allergy. Clin Mol Allergy (2005) 0.81
Plant virus expression systems for transient production of recombinant allergens in Nicotiana benthamiana. Methods (2004) 0.81
Purification and characterisation of relevant natural and recombinant apple allergens. Mol Nutr Food Res (2008) 0.81
Genetic engineering of allergens: future therapeutic products. Int Arch Allergy Immunol (2002) 0.80
Solution and high-pressure NMR studies of the structure, dynamics, and stability of the cross-reactive allergenic cod parvalbumin Gad m 1. Proteins (2014) 0.79
Production and characterization of an allergen panel for component-resolved diagnosis of celery allergy. Mol Nutr Food Res (2008) 0.79
Expression of the B subunit of the heat-labile enterotoxin of Escherichia coli in tobacco mosaic virus-infected Nicotiana benthamiana plants and its characterization as mucosal immunogen and adjuvant. J Immunol Methods (2004) 0.79
Allergy multivaccines created by DNA shuffling of tree pollen allergens. J Allergy Clin Immunol (2007) 0.79
Effects of established allergen sensitization on immune and airway responses after secondary allergen sensitization. J Allergy Clin Immunol (2006) 0.78
Mal d 2, the thaumatin-like allergen from apple, is highly resistant to gastrointestinal digestion and thermal processing. Int Arch Allergy Immunol (2008) 0.78
Cross-reactivity of mimotopes with a monoclonal antibody against the high molecular weight melanoma-associated antigen (HMW-MAA) does not predict cross-reactive immunogenicity. Melanoma Res (2005) 0.78
A non-allergenic Ole e 1-like protein from birch pollen as a tool to design hypoallergenic vaccine candidates. Mol Immunol (2012) 0.78
Use of a genetic cholera toxin B subunit/allergen fusion molecule as mucosal delivery system with immunosuppressive activity against Th2 immune responses. Vaccine (2007) 0.78
Exercise with latex sport bands represents a risk for latex allergic patients. Immunol Lett (2007) 0.78
A label-free indicator for tumor cells based on the CH2-stretch ratio. Analyst (2011) 0.77
Structural and bioinformatic analysis of the kiwifruit allergen Act d 11, a member of the family of ripening-related proteins. Mol Immunol (2013) 0.77
Vig r 6, the cytokinin-specific binding protein from mung bean (Vigna radiata) sprouts, cross-reacts with Bet v 1-related allergens and binds IgE from birch pollen allergic patients' sera. Mol Nutr Food Res (2013) 0.77
IgE sensitization profiles toward green and gold kiwifruits differ among patients allergic to kiwifruit from 3 European countries. J Allergy Clin Immunol (2004) 0.77
Selection of mimotopes of the cell surface adhesion molecule Mel-CAM from a random pVIII-28aa phage peptide library. J Invest Dermatol (2002) 0.77
Differential T-helper cell polarization after allergen-specific stimulation of autologous dendritic cells in polysensitized allergic patients. Int Arch Allergy Immunol (2015) 0.76
Pressure-temperature stability, Ca2+ binding, and pressure-temperature phase diagram of cod parvalbumin: Gad m 1. Biochemistry (2012) 0.76
Comparison of natural and recombinant forms of the major fish allergen parvalbumin from cod and carp. Mol Nutr Food Res (2008) 0.76
Molecular weight determination of high molecular mass (glyco)proteins using CGE-on-a-chip, planar SDS-PAGE and MALDI-TOF-MS. Electrophoresis (2010) 0.76
A Cross-Reactive Human Single-Chain Antibody for Detection of Major Fish Allergens, Parvalbumins, and Identification of a Major IgE-Binding Epitope. PLoS One (2015) 0.75
Epitope-specific antibody response to Mel-CAM induced by mimotope immunization. J Invest Dermatol (2005) 0.75
Recombinant Allergens in Structural Biology, Diagnosis, and Immunotherapy. Int Arch Allergy Immunol (2017) 0.75
Recombinant allergen methods. Methods (2014) 0.75
Diagnostic performance of single and multiplex IgE testing to recombinant parvalbumins in fish allergy. Ann Allergy Asthma Immunol (2012) 0.75
Physicochemical properties and thermal stability of Lep w 1, the major allergen of whiff. Mol Nutr Food Res (2010) 0.75
Enhanced Pru p 3 IgE binding activity by selective free fatty acid-interaction. J Allergy Clin Immunol (2017) 0.75